Insulet Corporation

Research Insulet Corporation (PODD) on Bullrun: valuation model: 7.2% overvalued, market cap USD 10.93B, P/E 36.7. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerPODD
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryMedical Devices
• CurrencyUSD
• Valuation signal7.2% overvalued
• Market capUSD 10.93B
• P/E36.7
• Financial periodFY2025
• RevenueUSD 2.71B
• Revenue growth30.7%
• Net incomeUSD 247.10M
• Free cash flowUSD 377.70M
• Gross margin71.6%

Valuation Snapshot

Bullrun's latest valuation model marks Insulet Corporation as 7.2% overvalued; latest market cap is USD 10.93B; P/E is 36.7.

About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication;

Frequently asked questions

Is Insulet Corporation overvalued or undervalued?

Bullrun's valuation model currently marks Insulet Corporation as 7.2% overvalued.

What is Insulet Corporation's market cap?

Insulet Corporation's market capitalization is USD 10.93B.

What is Insulet Corporation's P/E ratio?

Insulet Corporation's price-to-earnings (P/E) ratio is 36.7.

What does Insulet Corporation do?

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.